MicroRNA Market Size & Growth Forecast 2027–2036, By Segments (End-use, Application, Products & Services), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
MicroRNA Market size was estimated at USD 2.2 billion in 2026 and is projected to grow at a 13.21% CAGR from 2027 to 2036, exceeding USD 7.61 billion by 2036. The industry revenue for 2027 is assessed at USD 2.44 billion.
Get more details on this report
Request Free Sample ReportMicroRNA Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 44.63% share due to advanced genomics research, strong molecular diagnostics workflows, and extensive integration of microRNA analysis in pharmaceutical and clinical research applications.
- Asia Pacific growth is driven by expanding life sciences research capacity, adoption of precision medicine tools, and increasing use of RNA-based analysis in oncology and therapeutic development, reaching 14.34% CAGR.
Segment Momentum
- Biotechnology & Pharmaceutical Companies held a 48.86% share in 2026 because they extensively use microRNA platforms for drug discovery, biomarker validation, and therapeutic development with clear commercial pathways.
- Infectious Diseases is expanding fastest as research increasingly focuses on host-pathogen interactions, immune response analysis, and molecular approaches that support disease detection and translational research.
Market Expansion Drivers
- Increasing cancer and neurological disease prevalence accelerating microRNA diagnostic and therapeutic research.
- Advancements in genomic technologies enhancing biomarker discovery and precision medicine applications.
- Expanding pharmaceutical investment in RNA-based therapeutics driving microRNA platform commercialization.
Leading Market Participants
- Leading players in the MicroRNA market include Thermo Fisher Scientific Inc. (United States), QIAGEN N.V. (Netherlands), Merck KGaA (Germany), Takara Bio Inc. (Japan), LGC Group (United Kingdom), New England Biolabs, Inc. (United States), Bio-Techne Corporation (United States), Revvity, Inc. (United States), Illumina, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 2.2 billion
- 2027 Estimated Market Size: USD 2.44 billion.
- Projected Market Size: USD 7.61 billion by 2036
- Growth Forecast: 13.21% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Biotechnology & Pharmaceutical Companies (End-use) | Cancer (Application) | Services (Products & Services)
- Emerging Opportunity Segment: Academic & Government Research Institutes (End-use) | Infectious Diseases (Application) | Products (Products & Services)
Market Growth Drivers and Industry Trends
Increasing cancer and neurological disease prevalence accelerating microRNA diagnostic and therapeutic research
Increasing prevalence of cancer and neurological disorders is accelerating research activity in the MicroRNA market because microRNAs can influence gene expression and disease-related biological pathways. Their potential role as disease biomarkers creates opportunities for developing diagnostic approaches capable of supporting disease detection, classification, and monitoring, while their involvement in cellular processes also makes them relevant to therapeutic research. Growing demand for more precise molecular insights into complex diseases is encouraging researchers to investigate microRNA signatures across different disease conditions and patient populations.
Advancements in genomic technologies enhancing biomarker discovery and precision medicine applications
Advances in genomic technologies are strengthening the MicroRNA market by enabling researchers to identify, profile, and analyze microRNA expression patterns with greater efficiency. Improved sequencing, molecular analysis, and bioinformatics capabilities facilitate the discovery of disease-associated biomarkers and help researchers examine relationships between microRNA activity and individual biological characteristics. These developments support precision medicine by enabling more detailed molecular characterization of patients and creating opportunities to use microRNA profiles in disease stratification, treatment selection, and monitoring applications.
Expanding pharmaceutical investment in RNA-based therapeutics driving microRNA platform commercialization
Expanding pharmaceutical investment in RNA-based therapeutics will support MicroRNA market commercialization by increasing interest in technologies that can modulate gene expression through RNA-related mechanisms. MicroRNA research provides opportunities to develop therapeutic strategies based on restoring, inhibiting, or otherwise regulating specific microRNA activity associated with disease pathways. Greater industry attention to RNA technologies is also encouraging investment in delivery systems, target validation, formulation approaches, and translational research needed to move microRNA-based concepts from laboratory studies toward clinical applications.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing cancer and neurological disease prevalence accelerating microRNA diagnostic and therapeutic research | 2.00% | High | North America, Europe | High | Near Term |
| Advancements in genomic technologies enhancing biomarker discovery and precision medicine applications | 1.80% | High | North America, Asia Pacific | High | Mid Term |
| Expanding pharmaceutical investment in RNA-based therapeutics driving microRNA platform commercialization | 1.50% | Moderate | North America, Asia Pacific | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
Holding the largest share of the MicroRNA market, North America accounted for 44.63% in 2026, supported by a highly developed biomedical research ecosystem, substantial investment in molecular biology, and strong demand for advanced diagnostic and therapeutic technologies. MicroRNA research has gained importance because of its role in gene regulation and its potential applications in cancer research, disease diagnostics, drug development, and precision medicine. The region benefits from well-established research institutions, sophisticated laboratory infrastructure, and strong collaboration between academic, clinical, and biotechnology stakeholders. Increasing interest in biomarker discovery and molecular diagnostics is also expanding opportunities for MicroRNA-based applications. In addition, advances in sequencing, molecular analysis, and bioinformatics are enabling researchers to investigate MicroRNA functions more efficiently, strengthening the region's position across both research and translational applications.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is anticipated to experience the fastest growth, driven by expanding biotechnology and pharmaceutical research capabilities, increasing healthcare investment, and rising interest in precision medicine. Countries across the region are strengthening molecular research infrastructure and developing greater capacity for advanced genomic and diagnostic technologies, creating a broader environment for MicroRNA-related applications. The growing burden of complex and chronic diseases is also encouraging research into molecular biomarkers that can support earlier detection, disease classification, and treatment development. Furthermore, increasing collaboration between research organizations, healthcare institutions, and biotechnology stakeholders is helping accelerate the translation of molecular research into practical applications. As scientific capabilities expand and demand for innovative diagnostic and therapeutic approaches increases, Asia Pacific is expected to become an increasingly important contributor to the global MicroRNA market.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Biomarker Validation ExpertiseGermany emphasizes MicroRNA applications that strengthen translational research and high-quality molecular diagnostics. Research institutions and biotechnology companies continue investing in standardized analytical platforms that improve reproducibility and clinical relevance.
France 🇫🇷
Clinical Research CollaborationFrance supports the MicroRNA market through collaborative biomedical research focused on diagnostic innovation and personalized treatment strategies. Laboratories increasingly seek standardized workflows that facilitate reliable data generation and efficient clinical translation.
Italy 🇮🇹
Academic Discovery ProgramsItaly is strengthening the MicroRNA market through academic research and expanding molecular biology capabilities. Institutions are prioritizing biomarker-focused studies and laboratory technologies that enhance translational research across oncology and rare disease applications.
Japan 🇯🇵
Precision Medicine IntegrationJapan is advancing the MicroRNA market through growing interest in precision medicine and early disease detection. Researchers are focusing on reliable assay development and clinically applicable biomarker identification for oncology and chronic disease management.
South Korea 🇰🇷
Genomic Innovation PipelineSouth Korea continues expanding MicroRNA research across biotechnology, academic collaboration, and diagnostic innovation. Market participants prioritize scalable analytical technologies that support biomarker discovery and the development of targeted therapeutic approaches.
United States 🇺🇸
Translational Research FocusThe U.S. MicroRNA market benefits from extensive research into molecular diagnostics, biomarker discovery, and RNA-based therapeutics. Organizations are prioritizing technologies that accelerate clinical validation while supporting precision medicine and pharmaceutical development programs.
Segment Leadership and Growth Trends
MicroRNA Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Biotechnology & Pharmaceutical Companies (Largest Segment) vs Academic & Government Research Institutes (Fastest-Growing Segment)
Biotechnology & pharmaceutical companies represented the largest end-use segment of the MicroRNA market in 2026, accounting for a 48.86% share. Their strong position is driven by the growing use of microRNA technologies in drug discovery, biomarker development, therapeutic research, and molecular diagnostics. These organizations increasingly leverage microRNA profiling to understand disease mechanisms and identify potential therapeutic targets, while advances in precision medicine and molecular research continue to expand commercial applications.
Academic & government research institutes are emerging as the fastest-growing end-use segment as microRNA research expands across genomics, disease biology, and translational science. Increased investigation of microRNA functions and regulatory pathways is creating greater demand for sequencing, profiling, and analytical technologies within research environments. Broader research into molecular biomarkers and personalized disease mechanisms is further strengthening the role of these institutions in advancing microRNA applications.
Application Segment Analysis: Cancer (Largest Segment) vs Infectious Diseases (Fastest-Growing Segment)
The cancer application segment led the MicroRNA market in 2026, holding a 38.85% share, supported by extensive research into microRNA's role in tumor development, disease progression, diagnosis, and therapeutic response. MicroRNAs can provide valuable insights into gene regulation and molecular changes associated with different cancers, making them important tools for biomarker discovery and targeted research. The growing emphasis on precision oncology and molecular characterization of tumors continues to sustain demand for microRNA-based applications.
Infectious diseases represent the fastest-growing application segment as researchers increasingly investigate microRNA interactions with pathogens and host biological responses. MicroRNA profiling can support the identification of molecular biomarkers and improve understanding of disease mechanisms, creating opportunities for diagnostic and therapeutic research. Rising interest in advanced molecular approaches to infectious disease detection and treatment is further expanding the application of microRNA technologies.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Others | Biotechnology & Pharmaceutical Companies | Academic & Government Research Institutes |
| Application | Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, Others | Cancer | Infectious Diseases |
| Products & Services | Services, Products | Services | Products |
Competitive Landscape and Market Positioning
Key companies in the MicroRNA market:
1. Thermo Fisher Scientific Inc. (United States)
2. QIAGEN N.V. (Netherlands)
3. Merck KGaA (Germany)
4. Takara Bio Inc. (Japan)
5. LGC Group (United Kingdom)
6. New England Biolabs Inc. (United States)
7. Bio-Techne Corporation (United States)
8. Revvity Inc. (United States)
9. Illumina Inc. (United States)
The microRNA sector is witnessing rapid scientific advancement supported by expanding biomedical research. In the MicroRNA market, innovation is driven by improved profiling and diagnostic capabilities. Strong research collaboration across scientific ecosystems is accelerating discoveries, while new analytical tools are enhancing research precision.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. (United States) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| Merck KGaA (Germany) | |||||||
| Takara Bio Inc. (Japan) | |||||||
| LGC Group (United Kingdom) | |||||||
| New England Biolabs Inc. (United States) | |||||||
| Bio-Techne Corporation (United States) | |||||||
| Revvity Inc. (United States) | |||||||
| Illumina Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Formation Bio | May-26 | Formation Bio secured exclusive worldwide rights (excluding Greater China) to FHND-5032, an oral small-molecule miR-124 activator. This in-licensing agreement expands the company’s pipeline in autoimmune disease treatment and highlights a strategic shift toward incorporating early-stage microRNA-modulating assets to enhance the commercial viability and therapeutic breadth of RNA-targeted drug portfolios. |
| Prerna | Oct-25 | Prerna launched Cantel, a microRNA-based blood test for breast cancer screening in India. This deployment provides a minimally invasive diagnostic solution for early disease detection, reflecting the regional expansion of microRNA-based liquid biopsy technologies and increasing the commercial footprint of diagnostic microRNA products within the global healthcare market. |
| MI:RNA | Sep-25 | MI:RNA secured funding to accelerate the development of an AI-enabled diagnostic tool for early canine osteoarthritis detection. By integrating microRNA-based biomarker analysis with artificial intelligence, the initiative aims to enhance the precision of veterinary diagnostics, demonstrating the expansion of microRNA-based diagnostic applications into specialized non-human clinical markets. |
| Inspirna | Apr-25 | Inspirna ceased operations and terminated its microRNA-focused therapeutic platform development. The closure highlights ongoing commercialization hurdles for microRNA-based oncology candidates and reflects a strategic contraction in the biotechnology sector regarding the feasibility of early-stage RNA-targeted drug discovery platforms, impacting the overall competitive landscape for microRNA therapeutic developers. |
| NeuroSense Therapeutics | Apr-25 | NeuroSense Therapeutics reported Phase 2b PARADIGM trial results demonstrating that its therapeutic candidate, PrimeC, effectively modulates ALS-related microRNAs. The data supports the drug's disease-modifying potential and advances the clinical validation of microRNA-targeted interventions in neurodegenerative disorders, serving as a critical indicator for the therapeutic efficacy of RNA-modulatory approaches in neurological patient care. |
| Cardior Pharmaceuticals | Dec-24 | Novo Nordisk acquired Cardior Pharmaceuticals for up to €1.025 billion, incorporating the latter’s proprietary microRNA-blocking therapeutic pipeline. The transaction marks a significant consolidation in the RNA-targeted medicine space, strategically positioning Novo Nordisk to leverage microRNA-based modalities for cardiovascular and fibrosis-related disease treatment and accelerating the clinical development of specialized RNA-modulating assets. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
MicroRNA Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Workflow Stage | MicroRNA Profiling & Detection, MicroRNA Quantification, MicroRNA Validation, MicroRNA Functional Analysis |
| Technology Platform | Microarray, Quantitative PCR, Next-Generation Sequencing, In Situ Hybridization |
| Sample Type | Tissue Samples, Blood & Plasma, Urine, Cell Culture & Other Biological Samples |
MicroRNA Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Clinical Translation and Commercialization Opportunities |
|
| Biomarker Development Opportunity Mapping |
|
| Pharmaceutical Pipeline Opportunity Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the microRNA market generate?
What are the growth projections for the microRNA industry?
Why is pharmaceutical investment becoming increasingly important for microRNA commercialization?
How are genomic technology advances strengthening demand in the microRNA market?
Why do biotechnology and pharmaceutical companies lead the MicroRNA market?
Why are infectious diseases becoming the fastest-growing application in the MicroRNA market?
Why does North America dominate the MicroRNA market?
What is driving rapid MicroRNA market growth in Asia Pacific?
What are the prominent companies operating in the microRNA landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization